menu001.png

QTX153

Based on the structural properties of the HDAC6 enzyme and previous Quimatryx compounds, a new family of HDAC6 inhibitors with the ability to cross the blood-brain barrier has been designed and synthesized for central nervous system diseases.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3ª planta

   20009 San Sebastián

   Tel: 946 08 70 37

   www.quimatryx.com